Mural to Present and Host 1×1 Investor Meetings at the 14th Annual East Coast IDEAS Investor Conference
WALTHAM, Mass. and DUBLIN, June 05, 2024 (GLOBE NEWSWIRE) — Mural Oncology plc (Nasdaq:MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that Caroline Loew, Ph.D., CEO, will present at the East Coast IDEAS Investor Conference on June 13 at 9:15 a.m. EST. A webcast will be available at www.threepartadvisors.com/east-coast and ir.muraloncology.com.